Business
Precision BioSciences Announces Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting
DURHAM, N.C., April 28, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the
About this update from Precision Biosciences, Inc.
[{"type":"text","content":"DURHAM, N.C., April 28, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ARCUS® gene editing platform, today announced that the Company and its collaborators will present at the upcoming American Society of Genetic & Cell Therapy (ASGCT) Annual Meeting held virtually May 12-15, 2020.\n “The abstracts being presented by Precision and our collaborators this year at ASGCT underscore the differentiated capabilities of our proprietary ARCUS genome editing platform and the breadth of our emerging pipeline applying this technology in vivo,” commented Derek Jantz, Chief Scientific Officer and co-founder of Precision BioSciences. “These presentations demonstrate the specificity and versatility of ARCUS-driven genome editing in a variety of large animal models and provide further preclinical evidence of potentially meaningful and durable therapeutic impact on a range of genetic and infectious diseases. As we continue to validate ARCUS’ potential in vivo, we are focused on advancing our gene correction pipeline. We look forward to selecting a clinical candidate for our wholly owned PH1 program, expected in 2020, and, in partnership with Gilead, developing a potential cure for chronic hepatitis B infection, for which submission of an IND is currently targeted for 2021.” Precision BioSciences Presentations: Title: Engineering a Self-Inactivating Adeno-Associated Virus (AAV) Vector for ARCUS Nuclease Delivery Poster Session: Gene Targeting and Gene Correction, Abstract: 654Presenting Author: Hui Li, Ph.D., Precision BioSciences Title: A Gene Editing Approach to Eliminate Hepatitis B Virus Using ARCUS Meganucleases Poster Session: Gene Targeting and Gene Correction, Abstract 1057Presenting Author: Cassie Gorsuch, Ph.D., Precision BioSciences Partnered Presentations: Title: Therapeutic Efficacy of ARCUS Meganuclease Gene Editing - Arrest of Rod Degeneration and Restoration of Rod Function in a Transgenic Pig Model of Autosomal Dominant Retinitis PigmentosaOral Presentation: Gene Therapy for the Special Senses, Abstract 2 Date/Time: Tuesday, May 12, 2020, 10:30 – 10:45 a.m. ESTPresenting Author: Maureen Ann McCall, Ph.D., Professor, Department of Ophthalmology and Visual Sciences, University of Louisville Title: Evaluati...